SOUTHLAKE, Texas, July 11, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic […]
Other News
Adona Medical’s Next-Generation Heart Failure Management Platform Showcased at CSI Frankfurt 2023 Conference
Adona Medical’s Next-Generation Heart Failure Management Platform Showcased at CSI Frankfurt 2023 Conference PR Newswire Innovative platform designed for more personalized, tailored management of heart failure patients LOS GATOS, Calif. , July 10, 2023 /PRNewswire/ — Adona Medical , a Shifamed portfolio company that aims to deliver advanced interatrial shunting and hemodynamic monitoring systems for […]
AccurKardia’s AccurECG™ Analysis System Receives FDA 510(k) Clearance
NEW YORK–(BUSINESS WIRE)–AccurKardia, a medical technology company delivering clinical-grade ECG interpretation software, announced today that its flagship product, the AccurECG™ Analysis System (“AccurECG” or the “System”), has been granted FDA 510(k) clearance. AccurECG™ is a cloud-based, device-agnostic and fully automated electrocardiogram (ECG) interpretation software platform. The groundbreaking AccurECG™ software provides an array […]
First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study
DUBLIN–(BUSINESS WIRE)– FIRE1 today announced that the first U.S. patients have been successfully implanted with its FIRE1™ System for remote heart failure monitoring in an Early Feasibility Study. The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients. The first patient was implanted at Austin Heart, Texas, where […]
US FDA approves expanded indication for Novartis Leqvio® (inclisiran)
EAST HANOVER, N.J., July 10, 2023 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy1. […]
Canon Medical Introduces Aplio flex and Aplio go Ultrasound Systems to Address Healthcare Challenges in Europe
Amstelveen, Netherlands, July 10, 2023 – Canon Medical is delighted to announce the commercial availability of its two latest ultrasound systems, Aplio flex and Aplio go, in Europe. With the growing challenges faced by medical staff, including high workload and work-related musculoskeletal disorders, Canon Medical recognizes the importance of supporting healthcare […]
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the first patient has been enrolled […]
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has completed enrollment of the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial, evaluating the […]
Investor Insights: Gwen Watanabe – What Do You Look for in New MedTech Ventures?
McDermott + Bull Partner Ken Dropiewski talks with H.I.G. Capital Managing Director Gwen Watanabe about what her team looks for in prospective partners for new venture opportunities.
Investor Insights: Gwen Watanabe – How Do You See Venture in MedTech Looking in 2023?
McDermott + Bull Partner Ken Dropiewski talks with H.I.G. Capital Managing Director Gwen Watanabe about what she’s expecting to see in the venture capital space in 2023.
Recent
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging
Popular
- No commented posts yet